Biogen Q3 FY2026: revenue up 11.0%, EPS beats, GAAP loss
Biogen's third quarter is a growth story with a profit problem: revenue rose 11.0% to $2.80 billion and non-GAAP EPS of $2.62 beat the $2.03 consensus, yet the company reported a GAAP net loss of $20.6 million. Read it in two layers — the commercial portfolio is genuinely expanding, while deal charges and a shrinking multiple-sclerosis franchise keep the bottom line from following.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS was -$0.14 against $3.17 a year ago, while non-GAAP EPS of $2.62 came in well above the $2.03 consensus even though it was down from $4.81. The gap between the two lines is mostly accounting and deal bills: $283.8 million of acquired IPR&D tied to RayThera, $194.8 million of inventory step-up amortization and $66.5 million of restructuring. Strip those out and the business still earned money this quarter — just less than it did a year ago.
Revenue of $2.80 billion rose 11.0% (10.2% in constant currency) from $2.53 billion a year earlier. Product revenue of $2.09 billion did the work, up 13.1%, helped by the first full quarter of SYFOVRE and EMPAVELI after the Apellis acquisition. The drag was multiple sclerosis, where product revenue fell 13.4% to $919.3 million.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-11-03
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.